P- 62 RELAPSE OF AUTOIMMUNITY IN PATIENTS WITH LIVER TRANSPLANTATION FOR AUTOIMMUNE HEPATOPATHY AT A COLOMBIAN HEPATOLOGY CENTER

Introduction and Objectives

Autoimmune hepatopathies encompass a spectrum of diseases, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and overlap syndromes, which can progress to cirrhosis. Liver transplantation is an excellent management option for patients with advanced chronic liver disease. In our setting, the clinical outcome in terms of relapse rate for patients undergoing liver transplantation due to autoimmune hepatopathies is unknown. This study aims to characterize the relapse rates in patients transplanted for autoimmune hepatopathy at a Colombian liver transplant center.

Materials and Methods

A longitudinal retrospective descriptive study of a cohort of patients with autoimmune hepatopathy who underwent liver transplantation from November 2005 to December 2022.

Results

A total of 163 patients were transplanted for autoimmune pathology. The relapse rate within the first year was 2.6% (n=2) for AIH, 3.7% (n=1) for PBC, 9.2% (n=5) in overlap syndrome, and 16% (n=1) in PSC. Between the first and fifth year post-transplantation, the relapse rate was 13.1% (n=10) in AIH, 14.8% (n=4) in PBC, 29.6% (n=16) in overlap syndrome, and 0% in PSC. Between the fifth and tenth year, the relapse rate was 11.8% (n=9) in AIH, 22.2% (n=6) in PBC, 9.2% (n=5) in overlap syndrome, and 0% for PSC. The cumulative relapse rate at 10 years was 27.6% for AIH, 40% for PBC, and 16% for PSC.

Conclusions

In this population, the one-year, five-year, and ten-year relapse rates were similar to those reported in the literature at other liver transplant centers. These findings warrant further studies in the population with CBP to determine if there is any genetic susceptibility that predisposes to a higher relapse rate compared to other autoimmune liver diseases.